Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milabegron + tamsulosin to prolong gemcitabine bladder retention in NMIBC
ChiCTR2100049445Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mirabegron, tamsulosin and gemcitabine in bladder cancer, sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Bladder retention time of gemcitabine > 0.5 h after intravesical instillation. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
mirabegrontamsulosingemcitabine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR2100049445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049445.